SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-122717
Filing Date
2020-11-09
Accepted
2020-11-09 06:30:09
Documents
13
Period of Report
2020-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2035341d1_8k.htm   iXBRL 8-K 25205
2 EXHIBIT 99.1 tm2035341d1_ex99-1.htm EX-99.1 58044
  Complete submission text file 0001104659-20-122717.txt   268324

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20201109.xsd EX-101.SCH 3183
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20201109_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20201109_pre.xml EX-101.PRE 22708
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2035341d1_8k_htm.xml XML 3711
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 201296015
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences